569 related articles for article (PubMed ID: 29131306)
1. Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis.
Tricco AC; Ashoor HM; Soobiah C; Rios P; Veroniki AA; Hamid JS; Ivory JD; Khan PA; Yazdi F; Ghassemi M; Blondal E; Ho JM; Ng CH; Hemmelgarn B; Majumdar SR; Perrier L; Straus SE
J Am Geriatr Soc; 2018 Jan; 66(1):170-178. PubMed ID: 29131306
[TBL] [Abstract][Full Text] [Related]
2. Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis.
Veroniki AA; Ashoor HM; Rios P; Seitidis G; Stewart L; Clarke M; Tudur-Smith C; Mavridis D; Hemmelgarn BR; Holroyd-Leduc J; Straus SE; Tricco AC
BMJ Open; 2022 Apr; 12(4):e053012. PubMed ID: 35473731
[TBL] [Abstract][Full Text] [Related]
3. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
Battle CE; Abdul-Rahim AH; Shenkin SD; Hewitt J; Quinn TJ
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013306. PubMed ID: 33704781
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: systematic review and Bayesian network meta-analysis.
Jin BR; Liu HY
Neural Regen Res; 2019 May; 14(5):805-816. PubMed ID: 30688266
[TBL] [Abstract][Full Text] [Related]
6. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis.
Tricco AC; Soobiah C; Berliner S; Ho JM; Ng CH; Ashoor HM; Chen MH; Hemmelgarn B; Straus SE
CMAJ; 2013 Nov; 185(16):1393-401. PubMed ID: 24043661
[TBL] [Abstract][Full Text] [Related]
8. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
[TBL] [Abstract][Full Text] [Related]
9. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
[TBL] [Abstract][Full Text] [Related]
10. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943
[TBL] [Abstract][Full Text] [Related]
11. Identification of the optimal cognitive drugs among Alzheimer's disease: a Bayesian meta-analytic review.
Liang J; Li J; Jia R; Wang Y; Wu R; Zhang H; Hang L; Xu Y
Clin Interv Aging; 2018; 13():2061-2073. PubMed ID: 30425461
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
[TBL] [Abstract][Full Text] [Related]
14. Comparative Efficacy and Acceptability of Cholinesterase Inhibitors and Memantine Based on Dosage in Patients with Vascular Cognitive Impairment: A Network Meta-analysis.
Shi X; Ren G; Cui Y; Xu Z
Curr Alzheimer Res; 2022; 19(2):133-145. PubMed ID: 35048806
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Hansen RA; Gartlehner G; Webb AP; Morgan LC; Moore CG; Jonas DE
Clin Interv Aging; 2008; 3(2):211-25. PubMed ID: 18686744
[TBL] [Abstract][Full Text] [Related]
16. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
[TBL] [Abstract][Full Text] [Related]
17. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials.
Dou KX; Tan MS; Tan CC; Cao XP; Hou XH; Guo QH; Tan L; Mok V; Yu JT
Alzheimers Res Ther; 2018 Dec; 10(1):126. PubMed ID: 30591071
[TBL] [Abstract][Full Text] [Related]
18. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.
Kobayashi H; Ohnishi T; Nakagawa R; Yoshizawa K
Int J Geriatr Psychiatry; 2016 Aug; 31(8):892-904. PubMed ID: 26680338
[TBL] [Abstract][Full Text] [Related]
19. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
Kavirajan H; Schneider LS
Lancet Neurol; 2007 Sep; 6(9):782-92. PubMed ID: 17689146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
